Literature DB >> 21160471

Cancer: Small papillary thyroid cancers--is BRAF of prognostic value?

Paula Soares, Manuel Sobrinho-Simões.   

Abstract

The growing incidence in thyroid cancer results mainly from the detection of small or very small papillary thyroid carcinomas. The management of patients with such small tumors represents a major clinical challenge. Could evaluation of the BRAF status of such tumors aid risk stratification and patient management?

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21160471     DOI： 10.1038/nrendo.2010.213

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  10 in total

1.  PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.

Authors:  P Castro; A P Rebocho; R J Soares; J Magalhães; L Roque; V Trovisco; I Vieira de Castro; M Cardoso-de-Oliveira; E Fonseca; P Soares; M Sobrinho-Simões
Journal:  J Clin Endocrinol Metab       Date:  2005-10-11       Impact factor: 5.958

2.  Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness.

Authors:  Vítor Trovisco; Paula Soares; Ana Preto; Inês Vieira de Castro; Jorge Lima; Patrícia Castro; Valdemar Máximo; Tiago Botelho; Severina Moreira; Ana Margarida Meireles; João Magalhães; Alexander Abrosimov; José Cameselle-Teijeiro; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2005-05-19       Impact factor: 4.064

Review 3.  Follicular, papillary, and "hybrid" carcinomas of the thyroid.

Authors:  Patrícia Castro; Elsa Fonseca; João Magalhães; Manuel Sobrinho-Simões
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

4.  RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma.

Authors:  Kerry J Rhoden; Kristian Unger; Giuliana Salvatore; Yesim Yilmaz; Volodymyr Vovk; Gennaro Chiappetta; Mazin B Qumsiyeh; Jay L Rothstein; Alfredo Fusco; Massimo Santoro; Horst Zitzelsberger; Giovanni Tallini
Journal:  J Clin Endocrinol Metab       Date:  2006-04-04       Impact factor: 5.958

5.  Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases.

Authors:  Fulvio Basolo; Liborio Torregrossa; Riccardo Giannini; Mario Miccoli; Cristiana Lupi; Elisa Sensi; Piero Berti; Rossella Elisei; Paolo Vitti; Angelo Baggiani; Paolo Miccoli
Journal:  J Clin Endocrinol Metab       Date:  2010-07-14       Impact factor: 5.958

6.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.

Authors:  Paula Soares; Vítor Trovisco; Ana Sofia Rocha; Jorge Lima; Patrícia Castro; Ana Preto; Valdemar Máximo; Tiago Botelho; Raquel Seruca; Manuel Sobrinho-Simões
Journal:  Oncogene       Date:  2003-07-17       Impact factor: 9.867

7.  BRAF mutations are associated with some histological types of papillary thyroid carcinoma.

Authors:  Vítor Trovisco; Inês Vieira de Castro; Paula Soares; Valdemar Máximo; Paula Silva; João Magalhães; Alexander Abrosimov; Xavier Matias Guiu; Manuel Sobrinho-Simões
Journal:  J Pathol       Date:  2004-02       Impact factor: 7.996

8.  BRAF mutation in papillary thyroid microcarcinoma: the promise of better risk management.

Authors:  Mingzhao Xing
Journal:  Ann Surg Oncol       Date:  2009-01-22       Impact factor: 5.344

9.  BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.

Authors:  Mingzhao Xing; Douglas Clark; Haixia Guan; Meiju Ji; Alan Dackiw; Kathryn A Carson; Matthew Kim; Anthony Tufaro; Paul Ladenson; Martha Zeiger; Ralph Tufano
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

10.  Presence of BRAF V600E in very early stages of papillary thyroid carcinoma.

Authors:  Clara Ugolini; Riccardo Giannini; Cristiana Lupi; Giuliana Salvatore; Paolo Miccoli; Agnese Proietti; Rossella Elisei; Massimo Santoro; Fulvio Basolo
Journal:  Thyroid       Date:  2007-05       Impact factor: 6.568
  10 in total
  10 in total

1.  BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study.

Authors:  Giovanni Tallini; Dario de Biase; Cosimo Durante; Giorgia Acquaviva; Michele Bisceglia; Rocco Bruno; Maria Letizia Bacchi Reggiani; Gian Piero Casadei; Giuseppe Costante; Nadia Cremonini; Livia Lamartina; Domenico Meringolo; Francesco Nardi; Annalisa Pession; Kerry J Rhoden; Giuseppe Ronga; Massimo Torlontano; Antonella Verrienti; Michela Visani; Sebastiano Filetti
Journal:  Mod Pathol       Date:  2015-08-14       Impact factor: 7.842

Review 2.  Prognostic biomarkers in thyroid cancer.

Authors:  Paula Soares; Ricardo Celestino; Miguel Melo; Elsa Fonseca; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

3.  The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases.

Authors:  Catarina Eloy; Joana Santos; Paula Soares; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2011-07-28       Impact factor: 4.064

Review 4.  Molecular genetics and diagnosis of thyroid cancer.

Authors:  Yuri E Nikiforov; Marina N Nikiforova
Journal:  Nat Rev Endocrinol       Date:  2011-08-30       Impact factor: 43.330

Review 5.  Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification.

Authors:  Paula Soares; Antónia Afonso Póvoa; Miguel Melo; João Vinagre; Valdemar Máximo; Catarina Eloy; José Manuel Cameselle-Teijeiro; Manuel Sobrinho-Simões
Journal:  Endocr Pathol       Date:  2021-03-02       Impact factor: 3.943

6.  BRAF mutation correlates with recurrent papillary thyroid carcinoma in Chinese patients.

Authors:  F J Huang; W Y Fang; L Ye; X F Zhang; L Y Shen; R L Han; Q Wei; X C Fei; X Chen; W Q Wang; S Wang; G Ning
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

7.  Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer.

Authors:  Linda A Dultz; Shumon Dhar; Jennifer B Ogilvie; Keith S Heller; Dafna Bar-Sagi; Kepal N Patel
Journal:  Surgery       Date:  2013-10-02       Impact factor: 3.982

8.  Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer?

Authors:  Carmelo Nucera; Alfredo Pontecorvi
Journal:  Front Endocrinol (Lausanne)       Date:  2012-02-27       Impact factor: 5.555

Review 9.  Multikinase inhibitors use in differentiated thyroid carcinoma.

Authors:  Sina Jasim; Levent Ozsari; Mouhammed Amir Habra
Journal:  Biologics       Date:  2014-12-04

10.  V600EBRAF Inhibition Induces Cytoprotective Autophagy through AMPK in Thyroid Cancer Cells.

Authors:  Eva Jiménez-Mora; Beatriz Gallego; Sergio Díaz-Gago; Marina Lasa; Pablo Baquero; Antonio Chiloeches
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.